Stable luciferase expression does not alter immunologic or in vivo growth properties of GL261 murine glioma cells by Aaron J Clark et al.
Clark et al. Journal of Translational Medicine 2014, 12:345
http://www.translational-medicine.com/content/12/1/345RESEARCH Open AccessStable luciferase expression does not alter
immunologic or in vivo growth properties of
GL261 murine glioma cells
Aaron J Clark1,4*, Michael Safaee1, Taemin Oh2, Michael E Ivan1, Vamsi Parimi3, Rintaro Hashizume2,
Tomoko Ozawa1, Charles D James2, Orin Bloch2 and Andrew T Parsa2Abstract
Background: GL261 cells are murine glioma cells that demonstrate proliferation, invasion, and angiogenesis when
implanted in syngeneic C57BL/6 mice, providing a highly useful immunocompetent animal model of glioblastoma.
Modification of tumor cells for luciferase expression enables non-invasive monitoring of orthotopic tumor growth,
and has proven useful for studying glioblastoma response to novel therapeutics. However, tumor modification for
luciferase has the potential for evoking host immune response against otherwise syngeneic tumor cells, thereby
mitigating the tumor cells’ value for tumor immunology and immunotherapy studies.
Methods: GL261 cells were infected with lentivirus containing a gene encoding firefly luciferase (GL261.luc). In vitro
proliferation of parental (unmodified) GL261 and GL261.luc was measured on days 0, 1, 2, 4, and 7 following
plating, and the expression of 82 mouse cytokines and chemokines were analyzed by RT-PCR array. Cell lines were
also evaluated for differences in invasion and migration in modified Boyden chambers. GL261 and GL261.luc cells
were then implanted intracranially in C57BL/6 mice, with GL261.luc tumor growth monitored by quantitative
bioluminescence imaging, and all mice were followed for survival to compare relative malignancy of tumor cells.
Results: No difference in proliferation was indicated for GL261 vs. GL261.luc cells (p>0.05). Of the 82 genes
examined by RT-PCR array, seven (9%) exhibited statistically significant change after luciferase modification. Of these,
only three changed by greater than 2-fold: BMP-2, IL-13, and TGF-β2. No difference in invasion (p=0.67) or migration
(p=0.26) was evident between modified vs. unmodified cells. GL261.luc cell luminescence was detectable in the
brains of C57BL/6 mice at day 5 post-implantation, and tumor bioluminescence increased exponentially to day 19.
Median overall survival was 20.2 days versus 19.7 days for mice receiving implantation with GL261 and GL261.luc,
respectively (p=0.62). Histopathologic analysis revealed no morphological difference between tumors, and
immunohistochemical analysis showed no significant difference for staining of CD3, Ki67, or CD31 (p>0.05 for all).
Conclusions: Luciferase expression in GL261 murine glioma cells does not affect GL261 proliferation, invasion,
cytokine expression, or in vivo growth. Luciferase modification increases their utility for studying tumor immunology
and immunotherapeutic approaches for treating glioblastoma.
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A primary goal of glioblastoma (GBM) immunotherapy is
to harness the body’s immune system to target and eradi-
cate tumor cells, but the immunosuppressive microenvir-
onment in GBM has proven to significantly limit the
efficacy of immunotherapeutic strategies [1]. Preclinical
animal models of GBM are critical to the design and evalu-
ation of novel therapeutic strategies to overcome GBM-
mediated immunosuppression. However, many of the
existing models do not adequately recapitulate the tumor
microenvironment [2].
Glioma-261 (GL261) is a carcinogen-induced murine gli-
oma cell line initially generated by implanting methylcho-
lanthrene pellets into mouse brains [3]. When engrafted
intracranially into syngeneic mice, GL261-derived tumors
demonstrate nuclear pleomorphism, mitotic figures, neo-
vascularization, and pseudopalisading necrosis typical of
GBM [4]. GL261 cells can be implanted into immunocom-
petent C57BL/6 mice, and, in contrast to GBM xenograft
models, GL261 tumors demonstrate notable invasion into
adjacent normal brain [5]. Furthermore, GL261 orthotopic
tumors have been shown to be immunosuppressive [6],
with GL261 cells secreting TGF-β, and GL261 tumors con-
taining regulatory T-cell infiltration [7,8]. GL261 intracra-
nial growth in C57BL/6 mice is highly reproducible with
respect to length of host mouse survival [9] and, as a result,
the GL261-C57BL/6 model has been repeatedly used to
study immunotherapeutic strategies [10,11].
Transduction of tumor cells with lentivirus expressing
firefly luciferase allows for non-invasive, serial monitoring
of tumor growth and response to treatment in living ani-
mal subjects [12]. Our primary goal for the present study
was to evaluate the effect of lentiviral infection of GL261
cells, for expression of firefly luciferase, on immunomodu-
latory cytokine expression and for tumor growth in vivo.
Methods
Cell culture, viral transduction, and sample preparation
GL261 murine glioma cells (NCI Tumor Repository,
Frederick, MD) were grown and passaged in RPMI-1640
medium containing 10% fetal bovine serum (FBS) and 1%
penicillin-streptomycin in a humidified atmosphere of 5%
CO2. GL261 cells were transduced with HIV1-based lenti-
viral vector plasmid pHRSIN-CSGW-DINotI expressing
firefly luciferase (luc) under the control of the spleen
focus-forming virus promoter. Lentiviral vectors were gen-
erated by transfection of 293 T cells with plasmids encod-
ing the vesicular stomatitis virus G envelope, gag-pol, and
luc (generously provided by Dr. Y. Ikeda, Mayo Clinic,
Rochester, MN) [13]. Conditioned medium containing
viral vectors were harvested 48 hours post-transfection, fil-
tered (0.45 μm), and frozen until use. GL261 cells were
transduced using viral supernatants. Expression of luc was
confirmed by measuring luciferase activity (IVIS Luminaimaging station, Caliper Life Sciences), which we have pre-
viously demonstrated is highly correlated with cell number
[14]. The transduced cell lines will now be referred to as
GL261.luc. RNA was extracted using the RNeasy mini
protocol (QIAGEN). RNA concentration was determined
by spectrophotometry.
Proliferation assays
For analysis of in vitro proliferation, GL261 and GL261.luc
cells were transferred to a 96 well plate in quintuplicate at
a density of 5,000 cells per well. Proliferation was assessed
using the ATPlite Luminescence ATP Detection Assay
System (PerkinElmer) at days 1, 2, 4, and 7. To confirm
sustained luciferase expression over the relative time
course of the in vivo study, GL261, GL261.luc and U87.luc
cells were transferred to a 24 well plate at a density of
100,000 cells per well and luminescence signals were mea-
sured by microplate reader (Tecan Safire2) at days 7, 14,
and 21. Fold increase was determined by comparing the
change in luminescence to that of day 0. Each experiment
was repeated in triplicate. All results were verified using a
hemocytometer to determine cell count.
Real-time PCR array
RNA was extracted from GL261 and GL261.luc cells and
2 μg were reverse transcribed (RT2 First Strand, Cat#
PAMM-150Z, QIAGEN). Quantitative real-time PCR
was used to profile the expression of 82 genes encoding
inflammatory mouse cytokines and chemokines accord-
ing to the manufacturer’s instructions (RT2 Profiler PCR
Array, QIAGEN). Each experiment was performed in
triplicate.
Invasion and migration assayss
To assess the invasive capacity of tumor cells, we utilized
BD BioCoat Matrigel invasion chambers (BD Biosciences).
GL261 and GL261.luc cells were transferred to the inva-
sion chamber using the Cellstripper non-enzymatic cell
dissociation solution (Corning). Each cell line was plated
in triplicate. Prior to use, chambers were rehydrated with
RPMI-1640 for 2 hours at 37°C then plated at a density of
5 × 104 cells per well. After 12 hours of invasion through
Matrigel towards a 5% FBS gradient, invasion chambers
were fixed in 4% paraformaldehyde for 15 minutes, stained
with crystal violet dye, and washed in PBS. Cells were
counted using the AMG EVOS XL microscope. 10 high-
powered fields (HPF) were counted per well and averaged.
Migration was assessed in a similar fashion, except with-
out Matrigel placement in the chambers.
Intracranial tumor growth
For tumor cell implantation, mice were anesthetized
using a ketamine/xylazine mixture. A one cm incision
was made over the parieto-occipital bone, and bregma
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to puncture the skull 2 mm right lateral of bregma and
1 mm anterior to the coronal suture. Cells were injected
as previously described by Ozawa et al. at a density of
3 × 105 cells/3 μl [15]. In vivo quantitative biolumines-
cence imaging was conducted biweekly using the IVIS
Lumina imaging station (Caliper Life Sciences). In prep-
aration for imaging, mice were simultaneously anesthe-
tized with ketamine/xylazine and administered with
luciferin (D-Luciferin potassium salt, 150 mg/kg, Caliper
Life Sciences) via intraperitoneal injection, with mice
imaged 12 minutes after injection. Regions of interest
encompassing the intracranial area of signal were de-
fined using Living Image software and the total photons/
s/sr/cm2 (photons per second per steradian per square
cm) were recorded. Mice were observed daily until they
reached a moribund state, at which time they were eu-
thanized and their brains removed and processed for
histopathologic analysis. All animal procedures were ap-
proved by the University of California, San Francisco In-
stitutional Animal Care and Use Committee.
Immunohistochemistry
Sections were cut to 4-μm thickness, deparaffinized in xy-
lene, and rehydrated through graded alcohols to deionized
water. Antigen retrieval and endogenous peroxidase block
was carried out by standard operating procedure. Immu-
nohistochemistry (IHC) examination of GL261 tumor cells
was performed on FFPE sections using the Dako Mouse
EnVisionTM+HRP method. The following antibodies are
used for detection of (i) Ki-67 [monoclonal rat anti-mouse
Ki-67 antigen, clone TEC-3 (1:31250) (DAKO M7249)
DAKO, Glostrup, Denmark] (ii) CD31 [goat polyclonal
anti-mouse CD31 antigen, clone M-20 (1:1000) (sc-1506)
Santa Cruz Biotechnology, Dallas, Texas U.S.A] and (iii)
CD3 [Rabbit Polyclonal anti-mouse CD3 antigen, clone
F7.2.38 (1:200) (Dako A0452) DAKO, Glostrup, Denmark]
using DAKO auto-stainer.
Biomarker evaluation
The slides were digitized using NanoZoomer 2.0-HT:
C9600-13 scanner (Hamamatsu Photonics, Iwata City,
Japan) at 20X magnification. For Ki-67, CD31, and CD3
staining, six peripheral/ invasive tumor edge regions were
sampled with a fixed field of view of 0.427 mm2 per im-
munostained slide [16]. Areas of necrosis were discarded
during the evaluation and the senior histopathologist (VP)
was blinded to the experimental treatment. ImmunoRatio
software was used to quantify Ki67 and CD3 immunore-
activity, and CD31 positively stained endothelial capil-
laries were manually enumerated. The Ki-67 Labeling
Index (LI) was calculated as a percentage of positively
stained cells per the total number of tumor cells consid-
ered for evaluation.Statistical analysis
Differences in continuous variables between two groups
were compared by Student’s t-test. Kaplan-Meier estimates
were generated to illustrate the overall survival curves.
Animal deaths not related to tumor growth were cen-
sored. Differences in overall survival between groups were
compared by the log-rank test. All analyses were carried
out using PASW Statistics 18 (SPSS, Inc). P-values less
than 0.05 were considered statistically significant.
Results
Luciferase expression does not affect in vitro proliferation
GL261 cells were infected with luciferase containing
lentivirus (referred to as GL261.luc cells), and main-
tained in culture using in vitro growth conditions identi-
cal to that for unmodified GL261. Several weeks after
infection, GL261.luc cells were evaluated for luciferase
expression, with moderate luciferase activity detected
(Figure 1). Cells were then compared for in vitro growth
rate, using an ATP-based viability assay. Numbers of vi-
able cells in GL261 and GL261.luc cultures were com-
pared at day 0, 1, 2, 4, and 7, after plating. This analysis
revealed no significant difference in viable cells at any
time point (P > 0.05 at all time points, Figure 2).
Luciferase expression does not markedly change cytokine
expression
We next evaluated the effect of luciferase expression on
GL261 immunomodulatory cytokine and chemokine ex-
pression. For this, we used RT-PCR to determine the
mRNA expression level for 82 genes, with results show-
ing statistically significant differences between GL261
and GL261.luc cells in seven instances (Figure 3A,B). Of
these, the expression difference was greatest for BMP-2
(5.74-fold increased in GL261.luc), IL-13 (2.23-fold de-
creased in GL261.luc), and TGF-β2 (4.03-fold decreased
in GL261.luc). All other expression changes were less
than two-fold.
Luciferase expression does not affect GL261 in vitro
invasion or migration
We next compared the in vitro migration and invasion
of GL261 vs. GL261.luc cells. At 12 hours post seeding
in modified Boyden chambers, an average of eighty-two
GL261 cells/HPF had invaded through Matrigel coated
membranes, compared to eighty-six GL261.luc cells/
HPF (Figure 4A, P = 0.67). Similar results were obtained
when examining cell migration though a porous mem-
brane (Figure 4B, GL261, 57 cell/HPF; GL261.luc, 50
cells/HPF; P = 0.26).
Luciferase expression does not affect overall survival
A critical characteristic of an orthtopic glioma engraft-
ment model is the reproducible establishment of tumors
Figure 1 Luciferase activity in GL261.luc cells. U87MG cells, previously modified with the same lentivirus used here for GL261 modification
[14], were used as a control for assessing luciferase activity in transduced GL261 cells. U87MG.luc cells were plated at densities of 1x106, 0.5x106,
0.25x106, 0.1x106, 0.05x106, and 0.025x106 cells/well, from left to right. GL261 (negative control) and GL261.luc cells were plated at densities of
1x106, 0.5x106, and 0.25x106 cells/well.
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ase modification on GL261 cell tumorigenicity, we im-
planted GL261 and GL261.luc cells into the brains of
C57BL/6 mice. In the GL261.luc group, there was one
accidental death, which was censored for survival ana-
lysis. Median overall survival was 20.2 days for GL261-
bearing animals and 19.7 for GL261.luc-bearing animalsFigure 2 Luciferase expression does not affect proliferation
Luciferase expression by GL261.luc cells does not cause a
difference in proliferation, in vitro, as demonstrated by
ATP-based viability assay. The graph shows fold increase, relative
to day 0, as determined by comparing the luminescence at the
specified time point to the luminescence at time 0.(Figure 5A, P = 0.62), with no survival shorter than
19 days nor longer than 23 days for either cohort of
mice. Gross, macroscopic analysis of the brain for each
injected mouse showed readily observable tumor. Lucif-
erase activity of intracranially injected GL261.luc cells
was detectable by 5 days post-implantation, with steadily
increasing tumor luminescence evident days 8, 13 and
19 post-implantation (Figure 5B). Histologically, there
was no difference in appearance of the GL261 tumors
compared to GL261.luc (Figure 6). Likewise, there was
no significant difference in CD3, Ki67, or CD31 staining
between intracranial GL261 and GL261.luc tumors
(Table 1, Figure 6). To confirm that there was no change
in luciferase expression by GL261.luc over the relative
time course of the intracranial experiment, we examined
a defined number of GL261.luc cells for changes lucifer-
ase activity over 21 days. As expected based on the re-
sults in Figure 1, GL261.luc demonstrates less robust
luciferase activity compared to U87.luc, however lumi-
nescence activity of each cell line does not exhibit much
change over the course of the timeframe of our intracra-
nial experiment (Figure 7).
Discussion
In this study we have examined the effect of lentiviral
transduction and expression of firefly luciferase on murine
glioma cell biological properties, both in vitro and in vivo.
Among the issues we sought to address was whether lucif-
erase expression alters syngeneic host mouse response to
tumor, which, if realized, would detract from the benefit of
Figure 3 Differences in gene expression between GL261 and GL261.luc. Volcano plot (A) demonstrating the differences in gene expression,
for 82 cytokine and chemokine genes, between GL261.luc and unmodified GL261 cells. The horizontal grey line indicates the level at which a
significance difference (P = 0.05) exists. Points above that line represent genes whose expression is significantly different between the two cells.
The vertical grey lines indicate a fold change of 2: either increased or decreased by a factor of 2 in GL261.luc cells. Points outside of the vertical
lines represent genes which are more than 2-fold changed. A bar graph (B) depicts the extent of change for the seven genes whose expression
is significantly different between GL261.luc and GL261.
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our study goals, we generated murine GL261 cells with
stable expression of the luciferase gene. Analysis of paren-
tal and luciferase-modified cells in vitro revealed that lucif-
erase expression resulted in no significant effect on the
expression of 75 cytokine and chemokine genes, from 82
genes total that were examined. Gene expressions most
effected by the luciferase modification were BMP-2, up-
regulated approximately six-fold in luciferase-modified
cells, IL-13, and TGF-β2, with these latter two genes
down-regulated in luciferase-modified cells by more than
2- and 4-fold, respectively.
With respect to potential consequences of these gene ex-
pression changes, BMP-2 has been shown to induce differ-
entiation of glioma stem-like cells and, thus, modulate
chemosensitivity in vitro [17]. This luciferase modification-
associated change, therefore, should be taken into consid-
eration with future studies using the GL261.luc model
for testing chemotherapeutic agents. Less is known aboutFigure 4 Luciferase expression does not alter invasion or migration. T
migration (B) between GL261.luc and GL261 cells. Error bars indicate standthe role of IL-13 in glioblastoma biology. A recent clin-
ical study demonstrated that changes in plasma IL-13
levels, during patient treatment with a novel anti-
angiogenic agent, were associated with increased on-
target toxicities [18].
Significantly more is known about the role of TGF-β in
GBM biology. In addition to promoting glioma cell prolif-
eration, angiogenesis, and invasion, TGF-β enhances gli-
oma cell immune evasion [19]. Pharmacological inhibition
of TGF-β in animal models of glioma can induce tumor
rejection and increase survival, with associated increases
in tumor immune cell infiltration [20,21].
The identification of significant gene expression changes
in 8.5% of the genes surveyed suggests the need for a more
detailed analysis of transcriptome effects from lentiviral
luciferase modification, and further characterization of
GL261.luc will likely include the use of gene expression
arrays for a comprehensive analysis of transcriptional
changes. However, and despite the luciferase-associatedhe bar graphs showing no difference in in vitro invasion (A) and
ard error between triplicates.
Figure 5 Luciferase expression does not affect overall survival. Kaplan-Meier survival analysis (A) demonstrates no difference in overall
survival for mice implanted intracranially with either GL261.luc (dashed line) or GL261 cells (solid line). One animal in the GL261.luc group was
censored due to procedural-related death. In vivo quantitative bioluminescence imaging (B) demonstrates non-invasive monitoring of intracranial
tumor growth in animals implanted with GL261.luc cells.
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veyed, these changes had no significant effect on GL261
biologic properties. GL261.luc invasion and migration,
in vitro, was essentially indistinguishable from unmodified
GL261 cells, and, importantly, animals implanted intracra-
nially with GL261.luc cells had lengths of survival thatFigure 6 Histopatholgic and immunohistochemical analysis of
tumor specimens from GL261 and GL261.luc bearing animals.
Hematoxylin and Eosin (H&E) staining was used for conventional
morphologic analysis of tumor. Ki-67 staining was for examining
tumor cell proliferation, whereas C3 and CD31 staining was for T-cell
infiltration and tumor neovascularization, respectively. Magnification
is 200 X.were highly similar to mice receiving intracranial injection
of unmodified GL261 cells.
Likewise, there were no differences in T-cell infiltra-
tion into GL261 vs. GL261.luc tumors, as indicated by
similar numbers of CD3 positive cells, and suggesting
that cytokine expression differences, noted above, do not
have discernable effect on host immune response.
The current study did not include serial monitoring of
unmodified GL261 tumor growth. Non-invasive CT or
MR imaging, could be used for this purpose, although the
basis for doing so is not compelling, given the number of
similarities in biologic properties, between unmodified
and luciferase-modified GL261, we have identified. Fur-
thermore, in a recent study by Huang et al. evaluated the
growth of GL261.luc tumors in PDGF knockout C57BL/6
mice [22]. As would be expected, the growth and survival
curves demonstrated are very similar to those in the
present study. On day 15 post implantation, the re-
searchers performed contrast enhanced MRI of the mice
and demonstrated good correlation between MRI volumes
and bioluminescence. Of note, these results are in contrastTable 1 Luciferase expression does not significantly






CD3* 31.3 23.7 0.24
Ki67§ 67.3 48.3 0.18
CD31* 31.7 18.3 0.07
*Cells per high power field, §Percentage positive cells.
Analysis of CD3, Ki67, and CD31 in tumor harvested from GL261 and GL261.luc
bearing animals. For each marker, six random areas were counted and
averaged per tumor specimen.
Figure 7 In vitro luciferase expression of GL261.luc over 21 days.
GL261.luc cells were maintained in culture over 21 days. At day 0, 7, 14,
and 21, cells were seeded in 6-well plates at a defined density and
were evaluated for bioluminescence. GL261 and U87.luc cells were
used as negative and positive controls, respectively.
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group, which demonstrate a much higher range of lucifer-
ase activity [14]. This apparent inconsistency is to be ex-
pected based on the data presented in the current study
which show lower baseline luciferase activity for GL261.
luc compared to U87.luc.
Conclusions
GL261 engrafted tumors recapitulate several critical
characteristics of human GBM. Lentiviral transduction
with the luciferase gene results in stable luciferase ex-
pression, and allows for non-invasive imaging of tumor
growth. Luciferase expression may be associated with
change in the expression of a small subset of cytokine
genes, although this does not result in altered biologic
properties of GL261 tumor cells, or in tumors estab-
lished from GL261 cells.
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